Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Open accessThe DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Abstract
Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be effective for all individuals with an AUD. As such, there is a need to develop new, more effective, and diverse pharmacological treatment options for AUD with the hopes of increasing utilization and improving care. In this qualitative literature review, we discuss the efficacy, mechanism of action, and tolerability of approved, repurposed, and novel pharmacotherapies for the treatment of AUD with a clinical perspective. Pharmacotherapies discussed include: disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, and cannabidiol. Overall, many repurposed and novel agents discussed in this review demonstrate clinical effectiveness and promise for the future of AUD treatment. Importantly, these medications also offer potential improvements towards the advancement of precision medicine and personalized treatment for the heterogeneous AUD population. However, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, the efficacy of naltrexone and acamprosate are also suspected and inconclusive for preventing relapse in AUD [55].”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reductions in SUD severity were also found, suggesting improvements in SUD-related consequences and functioning.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While alcohol abstinence is desirable as the ultimate outcome of AUD treatment, only 16% of patients with AUD are able to achieve abstinence [55].”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a type of alcohol antagonist, disulfiram causes patients to experience strong physical discomfort after ingesting a small amount of alcohol, which may place patient at risk of the disulfiram-ethanol interaction reaction, at high risk of non-compliance and cannot effectively reduce craving, so it is basically not a preferred treatment for AUD unless supervised treatment with disulfiram can be”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The US Food and Drug Administration (FDA) has approved three drugs for abstinence: disulfiram, naltrexone and acamprosate.”
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×
“Ghrelin, a peptide produced by endocrine cells primarily in the stomach [261], is thought to regulate growth hormone secretion, food intake, and glucose homeostasis [262].”
BackgroundHasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 8×
“Furthermore, the lag between the age at which AUD onsets and the age of first AUD treatment has been estimated to be eight years on average [7].”
BackgroundInfluentialGrant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556 · cited 3×
“Alcohol use disorder (AUD) is a highly prevalent, chronic, relapsing condition characterized by an impaired ability to stop or control alcohol use despite clinically significant impairment, distress, or other adverse consequences [1, 2].”
BackgroundInfluentialPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930 · cited 1×
“In particular, a large scale trial (COMBINE), which compared acamprosate, naltrexone, and behavioral therapies, both individually and combined with each other, against placebo (N = 1383), found that acamprosate had no significant effect on drinking in comparison to placebo, either alone or in combination with naltrexo…”
BackgroundNaltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572 · cited 1×
“4 million people globally were estimated to have an AUD [3].”
BackgroundNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 1×
“In 1994, the FDA approved oral naltrexone to treat alcohol dependence after two independent 12-week trials, which included 97 and 70 participants, respectively, found that naltrexone significantly decreased drinking days and relapse rates [52, 53].”
BackgroundIs there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 1×
“By attenuating alcohol-induced opioidergic activity in the mesolimbic dopamine system, opioid antagonists like naltrexone, modulate the rewarding effects of alcohol (mediated by dopamine), thereby reducing alcohol consumption [50, 51].”
Background
Cited by
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Dharavath, R. N., Pina‐Leblanc, C., Tang, V. M., Sloan, M. E., Nikolova, Y. S., Pangarov, P., Ruocco, A. C., Shield, K. D., Voineskos, D., Blumberger, D. M., et al. (2023) · Frontiers in Neural Circuits · doi:10.3389/fncir.2023.1218737 · Cited by 92
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
van der Pol, K. H., Aljofan, M., Blin, O., Cornel, J. H., Rongen, G. A. P. J. M., Woestelandt, A.-G. B., & Spedding, M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00816-6 · Cited by 68
Baclofen for alcohol use disorder
Agabio, R., Saulle, R., Rösner, S., & Minozzi, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub3 · Cited by 75
Metadata
- Authors
- Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A.
- Affiliations
- University of California, Los Angeles (US)
- Los Angeles County Department of Public Health (US)
- Corresponding author
- Ray, Lara A.
- ORCID
- Venue
- Drugs
- Published
- 2022-02
- Volume
- 82
- Issue
- 3
- Pages
- 251-274
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8888464
- OpenAlex
- W4210944481
- Cited by
- 169
- References
- 318
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 52 · 2023: 35 · 2022: 14
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 7 d)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (K24AA025704, F31AA028976, F32AA029288)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- alcoholism, pharmacotherapy, drug repurposing, disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, cannabidiol, precision medicine, treatment access, treatment seeking
- MeSH terms
- Topiramate, Acamprosate, Alcohol Deterrents, Alcoholism, Baclofen, Disulfiram, Humans, Naltrexone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. https://app.cochat.ai/papers/10.1007/s40265-021-01670-3
- The paper
- Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022). Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. https://doi.org/10.1007/s40265-021-01670-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.